1 active not recruiting. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Active not recruiting 1 |
Follow Essential Thrombocythaemia: new trials by email Literature Review of Essential Thrombocythaemia trials Research Report on Essential Thrombocythaemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythaemia Patients Ropeginterferon alfa-2b (BESREMi®) - Essential Thrombocythaemia | Phase 3 | Active not recruiting | AOP Orphan Pharmaceuticals AG | 117 | 2023-12-04 | 2024-12-19 |
Thrombocythemia, Essential (1) · Thrombocytosis (1)
Blood Coagulation Disorders (1) · Blood Platelet Disorders (1) · Bone Marrow Diseases (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Hemorrhagic Disorders (1) · Myeloproliferative Disorders (1)
AOP Orphan Pharmaceuticals AG (1)
Austria (1) · Czechia (1) · France (1) · Germany (1) · Greece (1) · Hungary (1) · Italy (1) · Poland (1) · Romania (1) · Spain (1)